Los Angeles, CA—ChromaDex Corp. announced in a press release that it has received regulatory authorizations to sell its patented nicotinamide riboside chloride (branded Niagen) to consumers in the European Union and in Australia.
As the regulatory applicants and innovators, ChromaDex benefits from market exclusivity in Australia until December 2021 and in the EU until February 2025, according to the press release.
Related: ChromaDex Initiates Study on NR, Aging
“Dr. Jonny, what supplements do you personally take?” (PART TWO)
ChromaDex Continues Retail Expansion in Canada
ChromaDex CEO Rob Fried said in the release: “These regulatory notifications allow us to bring our clinically validated Tru Niagen to the people of Europe and Australia. We look forward to product launches with our distribution partners in these important markets.”